Abstract
Background
The estimated glomerular filtration rate (eGFR) is clinically used to approximate renal function and adapt drug dosage. Multiple myeloma is a hematological disease; its prognosis is largely influenced by renal function. We evaluated two commonly used GFR estimations, CKD-EPI and MDRD (CKD Epidemiology Collaboration; Modification of Diet in Renal Disease) in myeloma patients undergoing treatment with lenalidomide, a renally excreted immunomodulatory drug.
Methods
We prospectively studied 130 myeloma patients receiving lenalidomide treatment at our institution. At baseline and after 3 months, GFR estimations were performed based on the CKD-EPI and MDRD equations. We compared eGFR-dependent CKD staging and lenalidomide dosage assignments.
Results
Initially, most patients were classified as CKD stage I/II, using both equations. Comparison of baseline renal function via CKD-EPI and MDRD induced concordance of CKD staging in 83% of patients, while CKD-EPI improved CKD staging in 16% of patients (p = 0.11). CKD-EPI assigned 3% of patients to higher lenalidomide dosing as opposed to MDRD. Both equations showed improved eGFR after 3 months of lenalidomide treatment.
Conclusions
In our multiple myeloma patient cohort, CKD-EPI and MDRD led to similar CKD staging with minor differences in lenalidomide dosage assignment. Consistent with previous studies, eGFR improved under lenalidomide treatment. To standardize GFR estimation in myeloma patients, we suggest using the CKD-EPI equation.
Similar content being viewed by others
References
Heher EC, Rennke HG, Laubach JP, Richardson PG. Kidney disease and multiple myeloma. Clin J Am Soc Nephrol. 2013;8:2007–17.
Dimopoulos M, Kastritis E, Rosinol L, Bladé J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008;22:1485–93.
Bridoux F, Leung N, Hutchison CA, Touchard G, Sethi S, Fermand J-P, et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int. 2015;87:698–711.
Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120:4292–5.
San Miguel JF, Mateos MV, Ocio E, Garcia-Sanz R. Multiple myeloma: treatment evolution. Hematology. 2012;17:3–7.
Kleber M, Ihorst G, Deschler B, Jakob C, Liebisch P, Koch B, et al. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. Eur J Haematol. 2009;83:519–27.
Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28:4976–84.
Kleber M, Ihorst G, Udi J, Koch B, Wäsch R, Engelhardt M. Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal. Clin Lymphoma Myeloma Leuk. 2012;12:38–48.
Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371:906–17.
Dimopoulos MA, Cheung MC, Roussel M, Liu T, Gamberi B, Kolb B, et al. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Haematologica. 2016;101:363–70.
FDA. U.S. Food and drug administration: revlimid highlights of prescribing information; Reference ID: 4059396. 2011;3–5.
EMA. European Medicines Agency. Revlimid product information EMEA/H/C/000717-II/0089/G, Annex 1. 2009.
Lawson J, Switchenko JM, McKibbin T, Harvey RD. Impact of isotope dilution mass spectrometry (IDMS) standardization on carboplatin dose and adverse events. Pharmacotherapy. 2016;36:617–22.
Helou R. Should we continue to use the Cockcroft-Gault formula? Nephron Clin. Pract. 2010;116:172–86.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–70.
Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53:766–72.
Levey AS, Stevens L, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
KDIGO. Chapter 1: Definition and classification of CKD. Kidney Int Suppl. 2013;3:19–62.
Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:37–46.
Landis J, Koch G. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.
Engelhardt M, Ihorst G, Landgren O, Pantic M, Reinhardt H, Waldschmidt J, et al. Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years. Haematologica. 2015;100:1340–9.
Engelhardt M, Dold SM, Ihorst G, Zober A, Möller M, Reinhardt H, et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica. 2016;101:1110–9.
Engelhardt M, Domm A-S, Dold SM, Ihorst G, Reinhardt H, Zober A, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102:910–21.
Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014;99:232–42.
Dimopoulos MA, Christoulas D, Roussou M, Kastritis E, Migkou M, Gavriatopoulou M, et al. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: Dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol. 2010;85:1–5.
Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;1:31–41.
Kleber M, Cybulla M, Bauchmüller K, Ihorst G, Koch B, Engelhardt M. Monitoring of renal function in cancer patients: an ongoing challenge for clinical practice. Ann Oncol. 2007;18:950–8.
Levey A, Stevens L. Estimating GFR Using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate gfr estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010;55:622–7.
Levey AS, Inker LA, Coresh J. GFR estimation: from physiology to public health. Am J Kidney Dis. 2014;63:820–34.
Janowitz T, Williams EH, Marshall A, Ainsworth N, Thomas PB, Sammut SJ, et al. New model for estimating glomerular filtration rate in patients with cancer. J Clin Oncol. 2017;35:2798–805.
Terpos E, Christoulas D, Kastritis E, Katodritou E, Pouli A, Michalis E, et al. The chronic kidney disease epidemiology collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC. Eur J Haematol. 2013;91:347–55.
Matsushita K, Selvin E, Bash LD, Astor BC, Coresh J. Risk implications of the new CKD epidemiology collaboration (CKD-EPI) equation compared with the MDRD study equation for estimated GFR: the atherosclerosis risk in communities (ARIC) study. Am J Kidney Dis. 2010;55:648–59.
White SL, Polkinghorne KR, Atkins RC, Chadban SJ. Comparison of the prevalence and mortality risk of CKD in Australia using the CKD epidemiology collaboration (CKD-EPI) and modification of diet in renal disease (MDRD) study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle. Am J Kidney Dis. 2010;55:660–70.
Acknowledgements
The authors thank Prof. Dr. Hermann Einsele, University of Würzburg, Prof. Dr. Pieter Sonneveld, Erasmus MC Rotterdam, Prof. Dr. Christian Straka, Schön Clinic Starnberger See, Prof. Dr. Keith Stewart, Mayo Clinic Arizona & Rochester, Prof. Dr. Torben Plesner, Center Lillebaelt University of Southern Denmark and Prof. Dr. Justus Duyster, University of Freiburg, for their significant support, fruitful discussion and valuable suggestions. We are also highly obliged to the fruitful discussion with DSMM, GMMG, GIMEMA, EMN and IMWG myeloma experts. This work was supported by a restricted educational grant of Celgene and the Deutsche Krebshilfe (grants 1095969 and 111424 [to ME and RW]).
Author information
Authors and Affiliations
Contributions
AS, JG, MK, GI, ME, SZ performed the analysis; AS, JG, ET, GI, HR, RW, ME, SZ analyzed results; AS, JG, MK, ME, SZ prepared tables and figures; ME, RW, designed the research and AS, JG, ME, SZ wrote the paper. All authors approved the manuscript.
Corresponding authors
Ethics declarations
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB approval number EK 27/1/14) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Conflict of interest
The authors declare no competing financial interest. Our manuscript has not been published in any other scientific journal, nor has it been or will it be submitted or published elsewhere while being under consideration by Clinical and Experimental Nephrology.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Schmidts, A., Grünewald, J., Kleber, M. et al. GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study. Clin Exp Nephrol 23, 199–206 (2019). https://doi.org/10.1007/s10157-018-1626-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-018-1626-7